Vol 5, No 3 (2020)
Original article
Published online: 2020-09-07

open access

Page views 580
Article views/downloads 593
Get Citation

Connect on Social Media

Connect on Social Media

Soluble vascular cell adhesion molecule-1 in patients with non-valvular atrial fibrillation

Marzena Anaszewicz1, Joanna Wiśniewska1, Artur Mieczkowski1, Marcin Wasielewski1, Karol Suppan1, Beata Czerniak1, Kinga Lis2, Magdalena Żbikowska-Gotz2, Zbigniew Bartuzi2, Jacek Budzyński1
Medical Research Journal 2020;5(3):158-166.


Background: Disturbances in atrial microcirculation is recognized as a risk factor for atrial fibrillation (AF).

The aim of this study was to determine the associations between circulating soluble vascular cell adhesion molecule-1 (sVCAM-1) and the risk of AF and a one-year prognosis among consecutive inpatients.

Eighty consecutive inpatients hospitalized due to non-valvular AF and 80 consecutive inpatients admitted for exacerbation of chronic coronary syndrome (control group) were enrolled in the study. A cardiologic workup was performed and blood sVCAM-1 concentration was determined using the ELISA method.

Patients with AF had similar blood sVCAM-1 concentration compared to the control group. AF patients treated with new oral anticoagulants (NOACs) were significantly less likely to have a sVCAM-1 concentration elevated above the median value than patients treated with warfarin (34.2% vs 65.8%; p = 0.01). Patients with an increased percentage of fat mass (FM) had lower sVCAM-1 concentration. The risk of all-cause mortality and MACE during follow-up rose in individuals with elevated sVCAM-1 (≥ 1242 and ≥ 587 ng/ml, respectively) with (OR; 95%CI): 5.39; 1.57-18.45; p = 0.007, and 6.00; 1.18-30.37; p = 0.03, respectively. Risk of death rose with increase in the ratio of sVCAM-1 and FM (1.02; 1.00-1.04; p = 0.019).

Elevated sVCAM-1 was associated with all-cause mortality and MACE during one-year follow- up, but do not links the risk of AF. Use of NOACs may favorable affect endothelial function, A lower level of sVCAM-1 in obese patients may mediate the phenomenon of the “obesity paradox” in patients with AF.

Article available in PDF format

View PDF Download PDF file


  1. Nabi Aslan A, Baştuğ S, Ahmet Kasapkara H, et al. Coronary Artery Dominance May Predict Future Risk of Atrial Fibrillation. Acta Cardiol Sin. 2018; 34(4): 344–351.
  2. Harling L, Lambert J, Ashrafian H, et al. Pre-operative serum VCAM-1 as a biomarker of atrial fibrillation after coronary artery bypass grafting. J Cardiothorac Surg. 2017; 12(1): 70.
  3. Smiljic S. The clinical significance of endocardial endothelial dysfunction. Medicina (Kaunas). 2017; 53(5): 295–302.
  4. Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc Res. 2015; 105(3): 238–247.
  5. Willeit K, Pechlaner R, Willeit P, et al. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation. JAMA Cardiol. 2017; 2(5): 516–523.
  6. Verdejo H, Roldan J, Garcia L, et al. Systemic vascular cell adhesion molecule-1 predicts the occurrence of post-operative atrial fibrillation. Int J Cardiol. 2011; 150(3): 270–276.
  7. Seljeflot I, R Ulimoen S, Enger S, et al. Asymmetric Dimethylarginine Levels are Highly Associated With Atrial Fibrillation in an Elderly Population. Cardiol Res. 2012; 3(3): 109–115.
  8. Ruediger CD, John B, Kumar S, et al. Influence of ethnic background on left atrial markers of inflammation, endothelial function and tissue remodelling. Indian Pacing Electrophysiol J. 2018; 18(1): 1–5.
  9. Spangenberg A, Maghsoodi N, Dulnoan D, et al. Bone Mineral Density and Body Composition are Associated with Circulating Angiogenic Factors in Post-menopausal Women. Calcif Tissue Int. 2016; 99(6): 608–615.
  10. Anaszewicz M, Budzyński J. Clinical significance of nutritional status in patients with atrial fibrillation: An overview of current evidence. J Cardiol. 2017; 69(5): 719–730.
  11. Budzyński J, Anaszewicz M. The associations between atrial fibrillation and parameters of nutritional status assessment in the general hospital population - a cross-sectional analysis of medical documentation. Kardiol Pol. 2017; 75(3): 231–239.
  12. Li J, Solus J, Chen Q, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010; 7(4): 438–444.
  13. Adrielle Lima Vieira R, Nascimento de Freitas R, Volp AC. Adhesion molecules and chemokines; relation to anthropometric, body composition, biochemical and dietary variables. Nutr Hosp. 2014; 30(2): 223–236.
  14. Chen YL, Chang CL, Sun CK, et al. Impact of obesity control on circulating level of endothelial progenitor cells and angiogenesis in response to ischemic stimulation. J Transl Med. 2012; 10: 86.
  15. Engin A. Endothelial Dysfunction in Obesity. Obesity and Lipotoxicity. 2017: 345–379.
  16. Girerd N, Scridon A, Bessière F, et al. Periatrial epicardial fat is associated with markers of endothelial dysfunction in patients with atrial fibrillation. PLoS One. 2013; 8(10): e77167.
  17. Wycherley TP, Brinkworth GD, Keogh JB, et al. Long-term effects of weight loss with a very low carbohydrate and low fat diet on vascular function in overweight and obese patients. J Intern Med. 2010; 267(5): 452–461.
  18. Scridon A, Morel E, Nonin-Babary E, et al. Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace. 2012; 14(7): 948–953.
  19. Yu GIm, Jun SE, Shin DH. Associations of VCAM-1 gene polymorphisms with obesity and inflammation markers. Inflamm Res. 2017; 66(3): 217–225.
  20. Breitenstein A, Glanzmann M, Falk V, et al. Increased prothrombotic profile in the left atrial appendage of atrial fibrillation patients. Int J Cardiol. 2015; 185: 250–255.
  21. Chung NAY, Belgore F, Li-Saw-Hee FL, et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke. 2002; 33(9): 2187–2191.
  22. Namba S, Yamaoka-Tojo M, Kakizaki R, et al. Erratum to: Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017; 32(8): 983.
  23. Freestone B, Chong AY, Lim HS, et al. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med. 2005; 37(5): 365–372.
  24. Choudhury A, Freestone B, Patel J, et al. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis? Chest. 2007; 132(6): 1913–1919.
  25. Abe I, Teshima Y, Kondo H, et al. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm. 2018; 15(11): 1717–1727.
  26. Watson T, Shantsila E, Blann A, et al. Circulating progenitor cells in patients with atrial fibrillation and their relation with serum markers of inflammation and angiogenesis. Thromb Haemost. 2010; 104(2): 327–334.
  27. Tan Q, Zhang S, Qi X, et al. Permanent atrial fibrillation impairs the function of circulating endothelial progenitor cells. Postgrad Med. 2017; 129(2): 198–204.
  28. Peller M, Lodziński P, Ozierański K, et al. The influence of the atrial fibrillation episode duration on the endothelial function in patients treated with pulmonary veins isolation. Adv Clin Exp Med. 2017; 26(1): 109–113.
  29. Ogi H, Nakano Y, Niida S, et al. Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J. 2010; 74(9): 1815–1821.
  30. Ferri C, Desideri G, Valenti M, et al. Early upregulation of endothelial adhesion molecules in obese hypertensive men. Hypertension. 1999; 34(4 Pt 1): 568–573.
  31. Weymann A, Sabashnikov A, Ali-Hasan-Al-Saegh S, et al. Predictive Role of Coagulation, Fibrinolytic, and Endothelial Markers in Patients with Atrial Fibrillation, Stroke, and Thromboembolism: A Meta-Analysis, Meta-Regression, and Systematic Review. Med Sci Monit Basic Res. 2017; 23: 97–140.
  32. Zhang Lu, Ding Ru, Zhen Yi, et al. Relation of urotensin II levels to lone atrial fibrillation. Am J Cardiol. 2009; 104(12): 1704–1707.
  33. Polovina MM, Lip GYH, Potpara TS. Endothelial (dys)function in lone atrial fibrillation. Curr Pharm Des. 2015; 21(5): 622–645.
  34. Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, et al. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol. 2018; 84(2): 280–291.
  35. Kim JB, Joung HJ, Lee JM, et al. Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial. Trials. 2016; 17(1): 422.
  36. Abd El-Kader SM, Al-Jiffri OH. Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients. Afr Health Sci. 2018; 18(4): 873–883.
  37. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008; 1783(5): 886–895.